Efficacy of combination therapy with probiotics and mosapride in patients with <scp>IBS</scp> without diarrhea: a randomized, double‐blind, placebo‐controlled, multicenter, phase II trial

Choi, Chang Hwan; Kwon, Joong Goo; Kim, S. K.; Myung, Seung‐Jae; Park, K. S.; Sohn, Chong Il; Rhee, Poong–Lyul; Lee, K. J.; Lee, Oh Young; Jung, Hye‐Kyung; Jee, Sam Ryong; Jeen, Yoon-Tae; Choi, Myung‐Gyu; Choi, Suck Chei; Huh, Kyu Chan; Park, Hyokeun

doi:10.1111/nmo.12544

Cited by 36 publications

(22 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, abdominal discomfort and pain scores in treatment group 4 showed the best improvement in comparison to the placebo group. In patients suffering from constipation-predominant IBS, greater improvement was observed in stool frequency and consistency in the treatment groups 4 and 1 as compared to the placebo group [61].…”

Section: Probiotics In Health and Diseasementioning

confidence: 86%

Effects of Therapeutic Probiotics on Modulation of microRNAs

Davoodvandi

Marzban

Goleij

et al. 2020

Preprint

View full text Add to dashboard Cite

Probiotics are beneficial bacteria that exist within the human gut, and which are also present in different food products and supplements. They have been investigated for some decades, due to their potential beneficial impact on human health. Probiotics compete with pathogenic microorganisms for adhesion sites within the gut, to antagonize them or to regulate the host immune response resulting in preventive and therapeutic effects. Therefore, dysbiosis, defined as an impairment in the gut microbiota, could play a role in various pathological conditions, such as lactose intolerance, gastrointestinal and urogenital infections, various cancers, cystic fibrosis, allergies, inflammatory bowel disease, and can also be caused by antibiotic side effects. MicroRNAs (miRNAs) are short non-coding RNAs that can regulate gene expression in a post-transcriptional manner. miRNAs are biochemical biomarkers that play an important role in almost all cellular signaling pathways in many healthy and disease states. For the first time, the present review summarizes current evidence suggesting that the beneficial properties of probiotics could be explained based on the pivotal role of miRNAs.

show abstract

Section: Probiotics In Health and Diseasementioning

confidence: 86%

Effects of Therapeutic Probiotics on Modulation of microRNAs

Davoodvandi

Marzban

Goleij

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…In the IBS drug trial, it has been difficult to prove a significant effect on individual symptoms because of the high placebo effect. 36,37 Several previous studies of IBS patients have shown significant effects on overall symptoms or QOL, but the [38][39][40] Also, the relatively small sample size may be related to these results. Further large scaled studies are needed to determine the effect of phloroglucinol in individual symptoms.…”

Section: Discussionmentioning

confidence: 96%

The Effect of Phloroglucinol in Patients With Diarrhea-predominant Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled Trial

Shin

Kim

et al. 2020

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Background/AimsWe aim to evaluate the efficacy and safety of phloroglucinol in patients with diarrhea-predominant irritable bowel syndrome (IBS-D). MethodsSeventy-two patients with IBS-D who met Rome III criteria were 1:1 randomized in a parallel, double-blind design to receive phloroglucinol or placebo for 2 weeks. Patients were followed for 1 week after the end of treatment. The primary outcome was the proportion of responders, defined as those who answered "moderate or more of improvement" to the subject global assessment for at least 1 week of the 2-week treatment period. Secondary outcomes included the proportion of these patients during the 3-week period including 1 week of follow-up, IBS symptoms (abdominal pain/discomfort, diarrhea, urgency, mucus in stool, bloating, and passage of gas), stool frequency and consistency, and IBS quality of life (IBS-QOL). ResultsThe proportion of responders during 2-week treatment period tended to be higher in the phloroglucinol group than in the placebo group, although the difference did not reach statistical significance (55.6% vs 30.6%, P = 0.056). The proportion of responders during the 3-week period was significantly higher in the phloroglucinol group than in the placebo group (61.6% vs 30.6%, P = 0.013). Individual symptom scores, IBS-QOL, stool frequency and consistency tended to improve in the phloroglucinol group, but there were no statistical significances compared to those of the placebo group. No serious adverse events were reported in both groups. ConclusionsPhloroglucinol could be a safe and beneficial option for the management of overall IBS symptoms in patients with IBS-D. Further large scaled studies are warranted. (J Neurogastroenterol Motil 2020;26:117-127)

show abstract

“…The efficacy of Lactobacillus and Bacillus in the prevention and/or treatment of intestinal diseases such as diarrhea, colitis, irritable bowel syndrome, irritable bowel disease, and colorectal cancer was demonstrated ( Camilleri, 2006 ; Sazawal et al, 2006 ; Rafter et al, 2007 ; Pillai and Nelson, 2008 ; Ghouri et al, 2014 ; Urgesi et al, 2014 ; Choi et al, 2015 ; Matsuoka and Kanai, 2015 ; Majeed et al, 2016 ; Zhang et al, 2016 ). In particular, treatment of colorectal colitis in mice with probiotic B. subtilis restored balance in gut microflora: beneficial species of Bifidobacterium , Lactobacillus , and Butyricicoccus spp.…”

Section: Beneficial Effects Of Lactobacillus and mentioning

confidence: 99%

Secretome of Intestinal Bacilli: A Natural Guard against Pathologies

et al. 2017

View full text Add to dashboard Cite

Current studies of human gut microbiome usually do not consider the special functional role of transient microbiota, although some of its members remain in the host for a long time and produce broad spectrum of biologically active substances. Getting into the gastrointestinal tract (GIT) with food, water and probiotic preparations, two representatives of Bacilli class, genera Bacillus and Lactobacillus, colonize epithelium blurring the boundaries between resident and transient microbiota. Despite their minor proportion in the microbiome composition, these bacteria can significantly affect both the intestinal microbiota and the entire body thanks to a wide range of secreted compounds. Recently, insufficiency and limitations of pure genome-based analysis of gut microbiota became known. Thus, the need for intense functional studies is evident. This review aims to characterize the Bacillus and Lactobacillus in GIT, as well as the functional roles of the components released by these members of microbial intestinal community. Complex of their secreted compounds is referred by us as the “bacillary secretome.” The composition of the bacillary secretome, its biological effects in GIT and role in counteraction to infectious diseases and oncological pathologies in human organism is the subject of the review.

show abstract

Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double‐blind, placebo‐controlled, multicenter, phase II trial

Abstract: Combination therapy with probiotics and mosapride is effective for relief of symptoms in patients with non-diarrheal-type IBS. The study has been registered in the US National Library of Medicine (http://www.clinicaltrials.gov, NCT01505777).

Cited by 36 publications

References 56 publications

Effects of Therapeutic Probiotics on Modulation of microRNAs

Effects of Therapeutic Probiotics on Modulation of microRNAs

The Effect of Phloroglucinol in Patients With Diarrhea-predominant Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled Trial

Secretome of Intestinal Bacilli: A Natural Guard against Pathologies

Contact Info

Product

Resources

About